The trial is evaluating the safety and efficacy of revumenib (SNDX-5613, Syndax Pharmaceuticals) in adult and pediatric patients with relapsed/refractory KMT2A-r, or NPM1-m AML or ALL. Here, NPM1 is linked to acute lymphoblastic leukemia.